Therapeutic agent

Ritonavir

PreliminaryEvidence level
3Registered trials
1Conditions
0Study references

Evidence Summary

Evidence Level
Preliminary
Mechanism
Antiviral / Persistence, Enrollment: Actual, Sponsor Type: Other, Unknown / General
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
Investigational for listed conditions. 3 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.

Clinical Trials

3 trial(s) registered

NCT IDTitlePhaseStatus
NCT05965726RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID SymptomsPhase 2Completed
NCT05576662Paxlovid for Treatment of Long CovidPhase 2Completed
NCT05668091A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.Phase 2Completed

Key Studies / References

  • See linked studies